Signatories to IVI’s Establishment Agreement

- Bangladesh
- Bhutan
- Brazil
- China
- Ecuador
- Egypt
- India
- Indonesia
- Kazakhstan
- Kyrgyzstan
- Lebanon
- Liberia
- Malta
- Mongolia
- Myanmar
- Nepal
- Netherlands
- Oman
- Pakistan
- Panama
- Papua New Guinea
- Peru
- Philippines
- Republic of Korea
- Romania
- Senegal
- Sri Lanka
- Sweden
- Turkey
- Ukraine
- United States
- Canada
- Denmark
- France
- Kuwait
- Maldives
- Laos
- Uzbekistan
- IVI’s Global Outreach

- Australia
- Cambodia
- Thailand
- Vietnam
- Myanmar
- Sri Lanka
- India
- South Korea
- South Africa
- Mozambique
- Malawi
- Nicaragua
- Nicaragua
-  
The Year in Review

Eubiologics’ OCVs Euvichol® and Euvichol-Plus®, which was prequalified by the WHO in 2017

MOU signing between IVI and the Government of India (ICMR and the Department of Health and Family Welfare, of the Ministry of Health and Family Welfare)

IVI’s 20th Anniversary Celebration

Dr. Park Neung-hoo, Minister of Health and Welfare of the Republic of Korea, delivers his congratulatory speech at IVI’s 20th Anniversary Global Vaccine Forum.

Former UN Secretary General, Ban Ki-moon’s visit to IVI

US-Japan Emerging Infectious Diseases (EID) conference, co-hosted by IVI in Seoul on February 7

DCVBN annual general meeting co-hosted by IVI in Seoul on September 25

IVI addresses the Rotary International Districts 3640 & 3650 joint conference in Seoul with RI President John Germs in attendance

Vision
Developing countries free of suffering from infectious disease

Mission
Discover, develop and deliver safe, effective and affordable vaccines for global public health

Table of Contents

3 The Year in Review
4 Annual Letter
6 Vaccine Development & Delivery
8 Cholera
10 Typhoid
12 Dengue
13 MERS
14 Lab Highlights
16 Capacity Building
20 Impact
22 Board of Trustees
24 Our Partners
30 Finances
32 Leadership
Dear Friends,

It is my great pleasure to share IVI’s progress and achievements in 2017, a proud continuation of our 20 years of efforts to advance global health, and an opportunity to renew our commitment to discovery, development and delivery of safe, effective, and affordable vaccines for public health. IVI, based in Seoul, Republic of Korea is the world’s only international organization devoted exclusively to making vaccines available and accessible in developing countries.

In 2017, we celebrated our 20th anniversary and renewed our commitment to continue our mission into our third decade. Towards that end, we followed through with our strategic refresh, and stepped up efforts to implement a way forward; continuing our strides in cholera, typhoid fever and other programs, while also taking on new initiatives.

On the research and development front, 2017 saw a substantial increase in the availability of our first vaccine (the oral cholera vaccine) via EuBiologics due to the WHO’s licensure of Euvichol-Plus®, a plastic tube presentation of Euvichol®. The vaccine’s licensure increased EuBiologics’ annual OCV production to 25 million doses. In October, the WHO launched the Ending Cholera: A Global Roadmap to 2030, an ambitious strategy to reduce cholera deaths by up to 90 percent by 2030. The WHO calls IVI’s OCV a ‘Game Changer’ in the fight against the disease. With the OCV supply improving, IVI will shift emphasis from OCV development to OCV delivery in order to accelerate the vaccine’s use in the populations who need it the most.

As an example, IVI initiated the delivery of OCV (MOCA) in Mozambique (funded by the Korean International Cooperation Agency, KOICA) that will vaccinate more than 180,000 residents at risk of cholera. This project also entails the monitoring and evaluation of OCV to measure vaccine- and cost-effectiveness, plus the implementation of Water quality, Sanitation and Hygiene (WASH) to help prevent the disease and other infections.

IVI completed Phase I clinical trials of our second vaccine (Vi-DT typhoid conjugate) and started Phase II testing in collaboration with SK Chemicals of Korea and BioFarma of Indonesia. These efforts seek to accelerate clinical development and WHO prequalification of the typhoid conjugate vaccine. The Institute also launched a project to develop a new type of tuberculosis vaccine in conjunction with Harvard University. In our efforts to increase contributions to global health security, IVI joined the Global Health Security Agenda (GHSA) Steering Group as an advisor and became a member of the JEE Alliance.

We welcomed three new members to our Board of Trustees: Mr. Malcolm Sweeney, a senior finance executive; Dr. Chris Varma, an experienced entrepreneur and investor in the life sciences industry; and Dr. Ros-Mari Bålöw, the former Senior Research Officer from the Swedish International Development Agency (SIDA). Together, they bring a wealth of experience, insight and expertise to IVI within their respective fields.

In 2017, we expanded cooperation with our key stakeholders and new partners. At the request of the Korean Ministry of Health & Welfare (MOHW), IVI successfully initiated the effort to establish RIGHT (Research Investment in Global Health Technology), a public-private partnership fund involving the Bill & Melinda Gates Foundation and Korean industry, which intends to finance work on vaccines, drugs and diagnostics for global health. IVI also entered into an MOU with India to officially welcome the country as the third financially-contributing member state, after Korea and Sweden.

Meanwhile, IVI saw its financial sustainability improve significantly, with a much stronger outlook going into 2018 and 2019. We are confident that IVI is well-positioned to continue along its growth trajectory, made possible by the continued commitment and generosity of our supporters, friends and partners. I would like to express our profound gratitude to the Bill & Melinda Gates Foundation and the governments of Korea, Sweden, and India for their commitment to IVI. I also wish to thank the Korea Support Committee for IVI (KSC) and our many partners and collaborators.

Sincerely,

Jerome H. Kim, MD
We develop vaccines against infectious diseases which are of global health concern (e.g., MERS, Zika) and which affect developing countries (e.g., cholera, typhoid fever, dengue fever). Vaccine development and commercialization can be costly, lengthy and fraught with risk, and there are few incentives for companies to pursue development of a vaccine against neglected diseases and/or within a limited market.

IVI bridges this gap by partnering with vaccine manufacturers, governments and philanthropists, and by mobilizing resources and funding to develop and license vaccines for the public-sector market. We drive vaccine innovation by transferring our in-house technological innovations to vaccine manufacturers and partnering with them on training, clinical testing, and production.

In exchange for technology and support, manufacturers make a proportion of their product accessible to the public sector at a low price via an “access agreement”. Because we do not make a profit from intellectual property, we partner with multiple companies on tech transfer. This, in turn, helps ensure sufficient vaccine supply for the public-sector market.

We have brought to market a low-cost oral cholera vaccine that is WHO-prequalified and stockpiled by the WHO for emergency use. More than 20 million doses of the vaccine have been deployed to prevent and control cholera in about 20 countries. IVI is currently developing vaccines against typhoid fever and MERS, and has launched a research program on tuberculosis in collaboration with Harvard University.

A vaccination campaign was conducted through collaboration by Rotary International, IVI and local partners to immunize more than 27,000 residents at risk of cholera in Banke, Nepal from late 2016 to early 2017.

20,000,000
the number of doses of vaccine deployed to prevent and control cholera

20
the number of countries the vaccine has been deployed in
The Cholera Program aims to accelerate the development of oral cholera vaccines to meet the growing demand worldwide and to ensure optimal delivery of the vaccine to cholera-endemic and epidemic regions through various public-private partnership approaches.

Our cholera story dates back to 2006 when IVI reformulated an oral cholera vaccine (OCV). The technology was transferred to manufacturers and IVI partnered with some of them on development and commercialization. Since then, two oral cholera vaccines, Shanchol™ and Euvichol® and Euvichol-Plus® are WHO-prequalified and available for purchase.

### Development

<table>
<thead>
<tr>
<th>Product</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shanchol™</td>
<td>· Licensed in India in 2009; WHO-prequalified in 2011</td>
</tr>
<tr>
<td></td>
<td>· Used in vaccination campaigns (co-ordinated by IVI in 2015) against endemic and epidemic cholera in Ethiopia, Malawi and Nepal; tested in Bangladesh in a single dose regimen trial sponsored by IVI from 2014-2017</td>
</tr>
<tr>
<td>Euvichol®</td>
<td>· Licensed in South Korea in January 2015</td>
</tr>
<tr>
<td>Euvichol-Plus®</td>
<td>· WHO-prequalified in December 2015, thimerosal-free version prequalified in September 2016; Euvichol-Plus® was WHO-prequalified in August 2017</td>
</tr>
<tr>
<td></td>
<td>· Additional manufacturer and new plastic tube presentation of the vaccine increased global supply to 25 million doses for 2017</td>
</tr>
<tr>
<td>Cholvax®</td>
<td>· Under clinical development; clinical trials initiated in 2016 and continued in 2017</td>
</tr>
<tr>
<td>Incepta Vaccine, Bangladesh</td>
<td>· To be licensed in Bangladesh only; country has very high cholera burden of cholera</td>
</tr>
</tbody>
</table>

We continue to work on the oral cholera vaccine. A thimerosal-free version of Euvichol® was WHO-prequalified in 2016, and Euvichol-Plus®, a plastic tube presentation of Euvichol®, was WHO-prequalified in August 2017.

In addition to removing thimerosal from the vaccine, the use of a 600-liter fermenter and of plastic tubes allowed for the increase of production capacity to 25 million doses per year.

We are also working on optimizing vaccine use. The oral cholera vaccine is typically administered in two doses over a 14-day interval. However, a single-dose regimen was tested in collaboration with icddr,b on a large scale single-dose study in Bangladesh. Vaccinated participants were followed for 24 months after vaccination, showing the single dose is mildly protective for all cholera cases, while more protective for severe cholera. The use of a single dose vaccine would be advantageous in specific contexts such as outbreaks, refugee camps, and other emergency situations.

We continue to support delivery efforts of the OCV. IVI, with international partners and national health authorities, has conducted OCV vaccinations in Ethiopia, Malawi, and Nepal in 2015-2017. IVI, KOICA, and other partners will conduct a cholera vaccination campaign in Mozambique in 2018 with Euvichol-Plus®, vaccinating about 180,000 people.

We also conduct the Cholera Surveillance in Malawi (CSIMA) project, funded by the Bill & Melinda Gates Foundation (BMGF). CSIMA aims to establish a cholera surveillance platform in two districts of Malawi to assess the effectiveness of OCV following an emergency vaccination campaign in early 2015. This evidence will be useful to funders, policymakers, and countries who have cited the need for more data on the use of the vaccine in real-life situations to support decision-making on vaccine introduction.
The Typhoid Program aims to accelerate the development and introduction of new-generation typhoid vaccines in two ways: 1) development of new typhoid conjugate vaccines in collaboration with manufacturers; and 2) generation of evidence on the burden of typhoid in Africa.

We developed a typhoid conjugate vaccine using platform technology from the U.S. National Institutes of Health, conjugating the Salmonella Typhi Vi polysaccharide to diphtheria toxoid (Vi-DT). Conjugate vaccines have the advantage of conferring protection to infants (a high-risk group) against typhoid as well as generating T-cell-based immune responses. IVI transferred this technology to 3 manufacturers: SK Chemicals in South Korea, Biofarma in Indonesia, and Incepta in Bangladesh. We have received grants from the Gates Foundation to work with SK Chemicals (IVI will lead clinical development) and Biofarma (IVI will provide technical support). These collaborations aim to obtain vaccine licensure in their respective countries and then receive WHO prequalification for procurement in the Gavi/UNICEF market.

In 2017, a Phase I clinical trial for SK Vi-DT was completed in Manila, the Philippines. There were 144 study participants enrolled. The trial showed no vaccine safety concerns and a 100% seroconversion rate. Biofarma’s Phase I was also completed in 2017 and the results were similar. Phase II trials of the SK and Biofarma vaccine candidates are expected to start in Q1 and Q2 of 2018, respectively. Exploratory steps for a Phase III trial have been undertaken.

We conduct epidemiologic and socio-economic research on typhoid in Africa in order to close the knowledge gap on disease burden on the continent. While typhoid is recognized as a public health problem in Asia and Africa, information on its true burden is lacking, making it difficult to justify vaccination policy and to assess the impact of typhoid vaccination.

From 2011 to 2015, we conducted the Typhoid Fever Surveillance in Africa Program (TSAP), which evaluated the typhoid burden through standardized surveillance at 13 sites in 10 sub-Saharan African countries. One of the major findings of TSAP is confirmation that enteric fever caused by S. Typhi and non-typhoidal Salmonella is a significant problem in Africa. A follow-up study, Severe Typhoid in Africa (SETA) launched in 2016, is currently being implemented in various sites in 6 African countries. SETA aims to assess severe disease outcomes of invasive Salmonella infections and its economic burden. The results will guide policy and introduction of vaccines in this region of the world.

Countries collaborating with this study include: Burkina Faso, Madagascar, Ghana, Nigeria, Democratic Republic of the Congo and Ethiopia. IVI began surveillance activities in Burkina Faso, Ghana and Madagascar in 2016; and in Ethiopia, Nigeria, and Democratic Republic of the Congo in 2017. Analyses of samples collected during the project’s first year were performed at IVI during 2017. Monitoring activities and data collection are ongoing.
Dengue

IVI continued to make progress in dengue in 2017. Field studies were completed at all sites, including three studies in Africa, and additional lab testing is underway at IVI. Additionally, GDAC held its annual meetings, including the Asia-Pacific Dengue Prevention Board (APDPB) and the Americas Dengue Prevention Board (AmDPB). The APDPB meeting was held in Thailand in June 2017, and the AmDPB meeting was held in Brazil in August to address the topic of “Dengue in the time of Zika”. Additionally, GDAC continued working on capacity building with National Regulatory Authorities (NRAs). In addition to the NRAs of “first wave” countries for dengue vaccine registration (Brazil, Colombia, Indonesia, Malaysia, Mexico, Philippines, and Thailand), the NRAs of Vietnam and Sri Lanka were added in 2017. GDAC also started working with 6 developing country manufacturer licensees of the US NIH dengue vaccine candidate in 2017, supported by funding from the NIH, to develop a central database for clinical trial data generated by the manufacturing licensees.

Overall, 2017 has been a constructive and fruitful year for GDAC in terms of continued efforts to increase the readiness of low- and middle-income countries to introduce dengue vaccines.

GDAC is a global alliance to fight dengue and other Aedes mosquito-transmitted diseases under one strategic umbrella. Each partner has specific areas of expertise: IVAC focuses on health economics, strategic demand forecasting and vaccine development; Sabin focuses on communications and advocacy; PDC focuses on integration of vaccine and vector control, diagnostics, clinical case management, and pathogenesis. In addition to serving as the Secretariat of the consortium, IVI is responsible for disease burden and epidemiology, laboratory testing, modeling, policy and access, and regulatory issues. Working together, GDAC aims to promote data generation and synthesis, accelerate innovations in research, and support implementation of new and existing tools in the fight against dengue and Aedes-transmitted diseases.

GDAC was created in August 2016 by merging the Dengue Vaccine Initiative (DVI) with the Partnership for Dengue Control, with the intent of expanding the mission from dengue vaccines to a broader scope, encompassing comprehensive prevention and control measures for Aedes-transmitted diseases including dengue, Zika, yellow fever and chikungunya.

There are specific projects of GDAC conducted via support of the Bill & Melinda Gates Foundation as well as other funds from multiple industry partners. These projects include dengue burden field studies in Africa, Asia and South America, support for national regulatory authorities (NRAs) reviewing dengue vaccine candidates, and the convening of dengue prevention board meetings to address key issues in the prevention and control of Aedes-transmitted diseases. Other GDAC activities include the development of a centralized database for clinical trials of the U.S. NIH’s dengue vaccine candidate conducted by sub-licensees of this vaccine supported by funds from the NIH. Efforts are being made to obtain additional funding for proposed GDAC activities, with a focus on integrated vaccine/vector control.
In 2017, IVI’s Clinical Research Lab started the Korean Ministry of Food and Drug Safety (MFDS)’s project of studying the establishment and management of a Reference Laboratory for vaccine clinical evaluation. CRL has also been working on the development of vaccine evaluation systems for typhoid, Zika, and MERS-CoV, with support from the Ministry of Health and Welfare (MOHW).

Additionally, IVI is partnering with the Korean Centers for Disease Control and Prevention (KCDC) to develop a rapid test kit and ELISA for the detection of antigen/antibody of viral hemorrhagic fever viruses including the Ebola virus, as well as to develop neutralizing antibodies. Discussions are also ongoing with the Korean Ministry of Health & Welfare to support the development of a novel mucosal adjuvant.

CRL participated in the NIBSC/WHO collaborative studies funded by the Bill & Melinda Gates Foundation, a multi-national project involving seven laboratories from six countries, to evaluate an international standard serum for Typhoid Vi-conjugate vaccines. IVI’s in-house assay has been demonstrated to be the best non-commercial alternative among seven laboratories’ methods for typhoid vaccine clinical trials. As a result, a further collaborative study is planned in 2018 with all participants set to use IVI’s in-house ELISA as standard method. The report, BS2307, is accessible at WHO ECBS (http://www.who.int/biologicals/WHO_ECBS/en/). In addition, MFDS requested that CRL lead a project to develop additional human standard serum for a typhoid vaccine and awarded them a 3-year grant in early 2018.

Based on the result of the project “Broadly protective Shigella vaccine development” funded by PATH, CRL is seeking a grant for “Advancing process development, manufacturing, formulation and stabilization of a novel broadly-protective Shigella vaccine candidate for use in low-resource settings” in collaboration with PATH.

IVI’s Vaccine Process Development (VPD) Lab is developing several vaccine candidates and transferring vaccine technologies developed at IVI. Redevelopment of a potency assay, which is used for release of oral cholera vaccine (OCV), was completed in 2017. The assay will be qualified and transferred to Incepta Vaccine Ltd., a developing country vaccine manufacturer in Bangladesh for the release of their OCV (Cholvax). VPD is working on the development of conjugation processes and assays for several pneumococcal serotypes to develop a pneumococcal conjugate vaccine.

In 2017, VPD received two grants to work on a tuberculosis vaccine. A grant from the US NIH is aimed at the development of a TB vaccine using a Multi Antigen Presentation System (MAPS) in collaboration with Boston Children’s Hospital (Prof. Rick Malley) and Harvard Medical School (Prof. E. Rubin). The other grant, from the Korea Center for Disease Control and Prevention, seeks to develop a TB vaccine in collaboration with KCDC.
To bolster our vaccine development and delivery programs, we engage in capacity building within the vaccine industry. We help build knowledge in the vaccine spectrum through training, technology transfer, technical assistance, and educational partnerships. While our focus is on developing countries, we support vaccine professionals and organizations around the world.

One of the longest-running vaccinology courses in Asia, IVI’s Vaccinology Course has trained more than 1,200 people. The week-long course promotes vaccine sustainability in developing countries by training early- to mid-career vaccine professionals from low- and middle-income countries (LMICs) and fosters the development of collaborative networks and partnerships among LMICs.

The 17th Vaccinology Course, which was co-hosted by the Korea Human Resources Development Institute for Health and Welfare (KOHI), a state-run agency under the Ministry of Health and Welfare of Korea, brought together 147 participants from 19 countries. More than 30 experts from international agencies, including IVI and the World Health Organization; research organizations, including the U.S. National Institutes of Health; industry; universities; and non-profit organizations served as faculty members. Course evaluations from the participants found the quality of the course overall to be high. The trainees included 10 students from developing countries who were awarded fellowships. Planning is underway for the 18th Vaccinology Course, scheduled in September, 2018 at IVI.
IVI also collaborates with the Yonsei University School of Public Health to conduct a Master’s Program in Global Health Security for developing countries with support from the Korean International Cooperation Agency (KOICA). Since this program’s inception, IVI staff have provided lectures to the program’s students (~30 individuals from developing countries around the world) and will provide internships for up to 1/3 of the students.

IVI has taken a leadership role in an effort to establish the Research Investment for Global Health Technology (RIGHT) fund, a public-private partnership involving the Korean government, the Gates Foundation, and Korean biopharmaceutical companies to support the development of vaccines, drugs, diagnostics, and other select technologies for global health. The RIGHT fund will build international partnerships, harness the power of academic research, and leverage the translational science, technology, and manufacturing acumen of Korean companies and institutions to find promising new solutions to critical problems in global health.

Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance, speaks about oral cholera vaccines developed by IVI at a Developing Country Vaccine Manufacturers Network meeting which IVI co-hosted in Seoul in September 2017.

In 2017, IVI was accepted as an advisor to the Global Health Security Agenda (GHSA) Steering Group and as a member to the JEE Alliance, which allowed IVI to join a global network focused on achieving the common goals of preventing, detecting, and responding to infectious disease threats. IVI also continued its biannual graduate course in vaccinology via the Seoul National University Graduate School of Public Health.

In 2017, IVI also collaborated with the Yonsei University School of Public Health to conduct a Master’s Program in Global Health Security for developing countries with support from the Korean International Cooperation Agency (KOICA). Since this program’s inception, IVI staff have provided lectures to the program’s students (~30 individuals from developing countries around the world) and will provide internships for up to 1/3 of the students.

IVI has taken a leadership role in an effort to establish the Research Investment for Global Health Technology (RIGHT) fund, a public-private partnership involving the Korean government, the Gates Foundation, and Korean biopharmaceutical companies to support the development of vaccines, drugs, diagnostics, and other select technologies for global health. The RIGHT fund will build international partnerships, harness the power of academic research, and leverage the translational science, technology, and manufacturing acumen of Korean companies and institutions to find promising new solutions to critical problems in global health.

Dr. Seth Berkley, CEO of Gavi, speaks about oral cholera vaccines developed by IVI at a Developing Country Vaccine Manufacturers Network meeting which IVI co-hosted in Seoul in September 2017.

In 2017, IVI was accepted as an advisor to the Global Health Security Agenda (GHSA) Steering Group and as a member to the JEE Alliance, which allowed IVI to join a global network focused on achieving the common goals of preventing, detecting, and responding to infectious disease threats. IVI also continued its biannual graduate course in vaccinology via the Seoul National University Graduate School of Public Health.
In 2017, IVI scientists authored or co-authored 56 articles that were published in peer-reviewed scientific journals. Fifty were in the Scientific Citation Index (SCI) including high-profile journals such as *The New England Journal of Medicine* and *Nature Medicine, Science, Lancet Infectious Disease, Lancet Global Health*.

### Impact of the Oral Cholera Vaccine

A global cholera vaccine stockpile, managed by the WHO, was created in 2013 using the oral cholera vaccines developed by IVI. The stockpile created a previously non-existent market for oral cholera vaccines. It is estimated >20 million doses of the vaccine have been deployed in epidemic and endemic situations in nearly 20 countries so far (including India, Bangladesh, Ethiopia, Malawi, Iraq, South Sudan, Haiti, Tanzania, Cameroon, Guinea, Nepal, and the Democratic Republic of Congo).

Globally, OCV production was low, with demand exceeding supply. The WHO had to turn down requests from countries for supplies of vaccines that could not be filled because of the shortage.

That all changed when Euvichol® was approved in December 2015, followed by Euvichol-Plus®, employing a user-friendly plastic container, approved by the WHO Prequalification Program in December 2017. The addition of Euvichol-Plus® has increased global supply to more than 25 million doses for 2017, with the potential for further increased production in the future. More importantly, the extra capacity has contributed to reversing the cycle of low demand, low production, high price and inequitable distribution to one of increased demand, increased production, reduced price and increased access. Euvichol-Plus®, priced at about $1.30 per dose, is 25 percent cheaper than Euvichol®, and it will therefore enable aid and vaccine delivery organizations to procure more doses of OCV at the same cost.

With the vaccines and other tools now available to combat cholera, in October 2017 the WHO launched ‘Ending Cholera—A Global Roadmap to 2030’, an ambitious strategy aimed at reducing cholera deaths by 90 percent by 2030. The stage has been set for the vaccine to make bigger contributions to combating cholera worldwide.

While supply has increased, there is room for improvement in the uptake of the vaccine. Funders, policymakers, and countries have cited the need for more advocacy and evidence on use of the vaccine in real-life situations to support decision-making on vaccine introduction.
Board of Trustees

As of December 2017

MEMBERS-AT-LARGE

Prof. Adel A.F. Mahmoud (Chairperson)
Professor
Department of Molecular Biology,
Princeton University
U.S.A.

Mr. George Bickerstaff
(Vice Chairperson/Chair of Finance Committee)
Partner and Managing Director,
M.M. Dillon & Co.
U.S.A.

Dr. J. Joseph Kim
(Chair of Compensation & Benefits Committee)
President & CEO
Inovio Pharmaceuticals
U.S.A.

Prof. Fred N. Binka
(Vice Chancellor)
University of Health and Allied Sciences
Ghana

Dr. George R. Siber
(Chair of Scientific Committee)
Chief Scientific Officer
ClearPath Vaccines
U.S.A.

Dr. Hanna Nohynek
Chief Physician & Team leader
Vaccine Programme Development
National Institute for Health and Welfare (THL)
Finland

Mr. Lee Kyu Hyung
Advisor, Samsung Economic Research Institute
Republic of Korea

Representatives of WHO, UNDP, and Host Country (Republic of Korea)

Dr. Shin Young Soo
Regional Director
International Vaccine Institute
WHO Western Pacific Regional Office (WPRO)
Manila, Philippines

Mr. Lee Jang-keun
Director General
International Organizations Bureau
Ministry of Foreign Affairs
Republic of Korea

Dr. Jee Youngmee
Director General
Center for Pathology and Immunology
National Institute of Health
Korea Centers for Disease Control & Prevention
Republic of Korea

Representatives of State Parties to Establishment Agreement

Dr. Ros-Mari BÅLÖW
Sweden
To be named
Director General
Indian Council of Medical Research, New Delhi, India

Ex-officio

Dr. Jerome Kim
Director General
International Vaccine Institute

Mr. Malcolm Sweeney
Director of Finance EMEA
NComputing UK Ltd
UK

Board members with IVI senior staff
Governments, International Organizations and Major Donors

Republic of Korea
- Ministry of Health and Welfare (MOHW)
- Korea Centers for Disease Control & Prevention (KCDC)
- Ministry of Education (MDE)
- Ministry of Foreign Affairs (MOFA)
- Korea Health Industry Development Institute (KHIDI)
- Ministry of Food and Drug Safety (MFDS)
- Ministry of Trade, Industry and Energy (MOTIE)
- Ministry of Science, ICT and Future Planning (MSIT)
- National Research Foundation of Korea (NRF)
- Korea Research Institute of Bioscience and Biotechnology (KRIBB)

Korea International Cooperation Agency (KOICA)
- Bill & Melinda Gates Foundation
- Kingdom of Sweden
- Swedish International Development Cooperation Agency (SIDA)
- Republic of India
- German Federal Ministry of Education and Research (BMBF)
- World Health Organization (WHO)
- Samsung Life Public Welfare Foundation
- Korea Support Committee for IVI (KSC)

Nonprofit Organizations, Universities, Companies

PATH
- GlaxoSmithKline Biologicals (GSK)
- Sanofi Pasteur
- Shantha Biotechnics
- Incepta Vaccine
- Pfizer, Inc.

Takeda
- University of Biolefeld (UOB)
- University of Oxford
- Robert Koch Institute
- Abbott
- Takeda Pharmaceuticals International AG

Medical Science & Computing, LLC
- The Henry M. Jackson Foundation
- Economic Exchange Center
- Rotary International

LG Electronics
- SK Chemicals
- Kia Motors
- Export-Import Bank of Korea
- Rotary International District 3640
- Korea Association of Otorhinolaryngologists
- Community Chest of Korea
- Seoul National University R&DB Foundation
- Gyeongbuk Institute for Bio Industry
- Ewha Womans University
- Yonsei University
- YungHyun Foundation
- Chong Kun Dang Kochun Foundation
- Korea Exchange Bank Foundation

Kim & Chang Committee for Social Contributions
- EuBiologics, Co., Ltd.
- Shinil Enterprise (Seoul Cyber University)
- Green Cross
- SamjinGlobalnet Co., Ltd.
- Seoul Dairy Cooperative
- Celflithon
- Coreana Cosmetics
- Lee Sang Hee and Friends
- Sky 72 Golf & Resort
- Sartorius Korea Biotect. Co., Ltd.
- Korea Industrial Safety Association
- RAPHAS Co., Ltd.

SmartVisionCom
- Dr. Manki Song
- Diplomacy Magazine
- Well Born Pediatric Clinic
- Hana Financial Investment Co., Ltd.
- Korea Vaccine Co., Ltd.
- BOAZ ENT Clinic Network
- CCNC
- Genexine
- Atgen
- JINDOO IS Co., Ltd.
- Seoul Pediatric Clinic
- IMARKET Korea
- Korea Fashion Association

Companies, Organizations, Individuals in Korea

Our Partners

Core funding is provided by the Governments of the Republic of Korea and Sweden. We now welcome India, who recently became a financially contributing member state to IVI.

Public- and private-sector organizations and individuals also provide support, both monetary and in-kind, for the Institute’s research and programs. Prominent organizations and individuals in Korea also provide support thanks to efforts of the Korea Support Committee for IVI (KSC). Your generosity is deeply appreciated.
Collaborators

Ajou University
Republic of Korea

Armauer Hansen Research Institute (AHRI)
Ethiopia

AVIR Green Hills Biotechnology AG

Bandim Health Project

Bangladesh Institute of Child Health
Bangladesh

Beams Biotechnology Co., Ltd.

Bernhard Nocht Institute for Tropical Medicine
Germany

Bharat Biotech
India

BioFarma
Indonesia

Bio-Korea
Republic of Korea

BOSTON CONSULTING GROUP

Pusan National University
Republic of Korea

Catholic University
Republic of Korea

Celltrion

Centers for Disease Control, R.O.C.
Taiwan

Centre de Recherches Médicales de Lambaréné
Gabon

Centre MURAZ / AGIR
Burkina Faso

Chonbuk National University
Republic of Korea

Chonnam National University
Republic of Korea

Christian Medical College
India

Chungnam National University, Republic of Korea

Coalition against Typhoid

Coalition for Epidemic Preparedness Innovations

Developing Countries Vaccine Manufacturers Network (DCVMN)

Duke University Medical Center
U.S.A.

Embassy of the United States to Korea
Republic of Korea

Emory University
U.S.A.

Ethiopian Health and Nutrition Research Institute
Ethiopia

EuBiologics

Ewha Womans University
Republic of Korea

Fred Hutchinson Cancer Research Center
U.S.A.

Gavi, the Vaccine Alliance
Switzerland

Global Health Innovative Technology (GHIT) Fund
Japan

Global Health Investment Fund
U.S.A.

Global Health Security Agenda

Global Health Technology Coalition

Green Cross

Group for Technical Assistance
Nepal

Gyeongbuk Institute for Bio Industry
Republic of Korea

Hallym University
Republic of Korea

Hanyang University
Republic of Korea

icddr,b
Bangladesh

Incepa Vaccine
Bangladesh

Incheon National University
Republic of Korea

Indian Council of Medical Research
India

Indian Immunologicals Limited
India

Institut Pasteur
Republic of Korea

Institut Pasteur du Cambodge
Camodia

International Society for Vaccines (ISV)
U.S.A.

JEE Alliance

Johns Hopkins University – International Vaccine Access Center (IVAC)

John Snow, Inc.
U.S.A.

Kangwon National University
Republic of Korea

Kenya Medical Research Institute
Kenya

Kilimanjaro Christian Medical Centre
Tanzania

Konkuk University
Republic of Korea

Korea Center for Disease Control & Prevention
Republic of Korea

Korea Institute of Tuberculosis
Republic of Korea

Korea National Institute of Health (KNIH)
Republic of Korea

Korea Research Institute of Bioscience and Biotechnology (KRIBB)

Korea University
Republic of Korea

Kumasi Centre for Collaborative Research in Tropical Medicine
Ghana

Kyunghoe University
Republic of Korea

LG Chem
Republic of Korea

Mahidol University
Thailand

Medigen Vaccine Biologics Corp.
Taiwan

Metroosalud ESE / Unidad Hospitalaria communa Santa Cruz, Medellin
Colombia

Ministry of Food and Drug Safety
Republic of Korea

Ministries of Health
Ethiopia, Malawi, South Sudan

Ministries of Public Health
Brazil, Colombia, South Sudan

Ministry of Health and Population
Nepal

National Institute for Communicable Diseases (NICD)
South Africa

National Institute of Cholera & Enteric Diseases (NICED)
India

National Institute of Hygiene and Epidemiology (NIHE)
Vietnam

National Institutes of Health (NIH)
U.S.A.

Oromia Regional Health Bureau
Ethiopia

Oxford Economic Forecasting
UK

Pan American Health Organization (PAHO)

Panacea Biotec Ltd.
India

Patan Hospital
Nepal

PATH
U.S.A.

Pohang University of Science and Technology (POSTECH)
Republic of Korea

Programa de Estudio y Control de Enfermedades Tropicales (PECET), Universidad de Antioquia
Medellin, Colombia

Sabin Vaccine Institute
U.S.A.

Sanofi Pasteur
France

Secretaria de Salud Medellin, Colombia

Sejong University
Republic of Korea

Seoul National University
Republic of Korea

Shanha Biotechnics
India

SK Chemicals
Republic of Korea

Stanford University
U.S.A.

Takeda Pharmaceutical Company Limited
Japan

Technical University of Berlin (TUB)
Germany

Transgovernment Enterprise against Pandemic Influenza of Korea (TEPIK)

UNICEF
Nepal

United States Centers for Disease Control and Prevention (CDC)
U.S.A.

University of Alabama at Birmingham, U.S.A.

University of Antananarivo
Madagascar

University of Antioquia
Colombia

University of Arizona
U.S.A.

University of Arkansas
U.S.A.

University of British Columbia
Canada

University of Buckingham
U.K.

University of California
U.S.A.

University of California, Los Angeles
U.S.A.

University of California, San Francisco
U.S.A.

University of Colorado
U.S.A.

University of Florida
U.S.A.

University of Gezira
Sudan

University of Gothenburg
Sweden

University of Melbourne
Australia

University of Ougadougou
Burkina Faso

University of Oxford
UK

University of Queensland
Australia

University of Vermont
U.S.A.

University of Virginia
U.S.A.

University of Wisconsin
U.S.A.

Vallbiotech
Vietnam

Walter Reed Army Institute of Research (WRAIR)
U.S.A.

Washington University
U.S.A.

Wellcome Trust Sanger Institute
UK

WHO Initiative for Vaccine Research (IVR)

WHO Programme for Immunization Preventable Diseases (IPD)
Nepal

WHO Regional Office for Europe (EURO)

WHO Regional Office for South-East Asia (SEARO)

WHO Regional Office for the Western Pacific (WPRO)

World Health Organization (WHO)

Yonsei University
Republic of Korea
Korea Support Committee for IVI

Established in 1998, the Korea Support Committee for IVI (KSC) is a nonprofit organization based in Seoul, Korea that mobilizes local support for IVI. KSC consists of prominent leaders from government, industry and academia in Korea who contribute their time and expertise to support IVI.

Honorary President
(Vacancy)

President
Prof. CHO Dong-Sung, President, Incheon National University

Chairman of the board
Prof. PARK Sang-Chul, Chair Professor, Chonnam National University

Vice Presidents
Dr. PARK Mahnhoon, CEO, SK Chemical Life Science Biz

Mr. SHIN Young-Jin, CEO, President L&M Co., Ltd.

Executive Advisor
Prof. CHO Wan-Kyoo, Former President, Seoul National University / Former Minister of Education

Chief Advisor
Prof. PARK Sang-Dai, Professor Emeritus, Seoul National University / President, the National Academy of Sciences, Republic of Korea

Legal Advisor
Mr. CHOI Sang-Yup, Lawyer, Former Minister of Justice / Vice Prosecutor-General

Executive Director
Dr. KIM Duck Sang, CEO, Santorius Korea Biotech Co., Ltd.

Advisors
Mr. CHAE Hee-Byung, Board Member, International Rotary

Dr. CHUNG Won-Shik, Former Prime Minister

Mr. KANG Choong Hyun, President & CEO, Samjin Globalnet Co., Ltd.

Mr. KANG Shin-Ho, Chairman, Dong-A Sico Group

Mr. KIM Doo-Hyun, Chairman, Chong Kun Dang Kochun Foundation

Prof. KIM Nak Doo, Professor Emeritus, Seoul National University College of Pharmacy

Prof. KIM Sang-Joo, Former President, the National Academy of Sciences, Republic of Korea

Prof. KWON E. Hyock, Professor Emeritus & Former President, Seoul National University / Former Minister of Education / Public Health / Environment

Dr. LEE Gil-ya, President, Gachon Gil Foundation

Prof. LEE Ho-Wang, Former President, the National Academy of Sciences, Republic of Korea

Mr. LEE Kyu Hyung, Advisor, Samsung Research Institute, Former Ambassador of the Republic of Korea in China and Russia, Former Deputy Minister of MOFA

Prof. LEE Sang Sup, Professor Emeritus, Seoul National University College of Pharmacy

Amb. PARK Soo-Gil, President, World Federation UN Association / Former Permanent Representative of the Republic of Korea to the UN

Prof. RHEE Shang-Hi, Chairman, Greentlife Intellectual Network, Former President, Korea Patent Attorneys Association / Former Minister of Science & Technology

Dr. SHIN Seung-Il, Member of the Board, Global Solutions for Infectious Diseases, USA / Chairman of the Board, ChildFund Korea

Prof. SON Bang Ho, Chairman, Korea Community Sharing Campaign, Professor Emeritus, Seoul National University

Dr. YOON Hong-Geun, Chairman & CEO, GENESIS BBQ Group

Prof. YU Jae-Cheon, Former President, Sangi University

Mr. WON Dae Yunn, Chairman, Korea Fashion Association

Board of Trustees
Dr. BAIK Yeong Ok, CEO, EUbiologics Co., Ltd.

Ms. CHANG Grace, CEO, Shinhan Customs Service Inc.

Mr. CHO Won Tae, President & CEO, Korean Air Lines

Dr. CHOI Davis, President, Korea Vaccine Co., Ltd.

Prof. CHOI Hak-Yoo, President, Dong Woo Chem. Corp.

Mr. CHUN Hong Jae, CEO, Chun Loss Prevention Co., Ltd.

Prof. CHUNG Chan Bok, President & CEO, SK Bioland

Prof. HUH Kap Bum, Professor Emeritus & Former Dean, Yonsei University College of Medicine

Mr. HUH Eun Chul, President, Green Cross Corp.

Mr. JEFFREY D. Johns, Chairman, Partners for the Future Foundation

Dr. JEONG Dohyeon, CEO, RAPHAS Co., Ltd.

Dr. KANG Dahee, Professor, Seoul National University College of Medicine

Dr. KIM Byeong Gwan, President, SMG-SNU Boramae Hospital

Prof. KIM Ho, Professor, Graduate School of Public Health, Seoul Nat’l Univ.

Mr. KIM Kyong Ho, Chairman, Hankyung Instrument & ENG Co., Ltd

Prof. KIM Kyung Jin, Professor, Department of Brain Science, Daegu Gyeongbuk Institute of Science & Technology

Ms. KIM Soo Hee, Chairman, Global Yoomyung Co., Ltd.

Prof. KIM Sun Young, Professor, Seoul National University College of Natural Sciences

Mr. KIM Young Je, President & CEO, Sky 72 Golf Club

Dr. LEE Sang-Kyun, Board Chair, Shin-II Education Foundation

Mr. LEE Jae Hoo, Senior Partner, Kim & Chang

Dr. LEE In Jung, President & CEO, Taein Co., Ltd.

Dr. LEE Myung Chul, President, The Korean Academy of Science Technology

Ms. LEE Kyung Ja, Chairman, Association of Research & Development for Experience Education

Prof. LEE Young Soon, Professor Emeritus, Seoul National University

Dr. LIM Bok-Kyu, Chairman, Magazine “Diplomacy”

Prof. PARK Ky-Yong, Professor, Department of Biology, Sunchon National University

Prof. PARK Kyung A, Professor, Yonsei University College of Medicine

Mr. PARK Nam Soo, President & CEO, Coreana Cosmetics

Dr. YOON Eun Key, President, Korea Collaboration Association, Chair Professor, ASSIST (Seoul School of Integrated Science & Technology)

Auditors
Mr. KIM Yong-Won, Partner, Samil PricewaterhouseCoopers

Prof. HONG Seung Hwan, Professor, Seoul National University College of Natural Sciences

Prof. SONG Jin Won, Professor, Korea University College of Medicine

Ms. SONG Kay, CEO, BT&I

Mr. CHO Stanley, CEO, SmartVisionCom

Mr. SHIN Hyun II, Chairman, Bomoon Co.

Prof. SUNG Young Chul, Professor, Dept. of Life Sciences, POSTECH

Dr. YANG Yoon Sun, CEO & President, MEDIPOST

Prof. YIM Jeong-bin, Chair Professor, Soon Chun Hyang University

Mr. YU Hack Soo, President & CEO, Coreana Cosmetics

Dr. YOON Eun Key, President, Korea Collaboration Association, Chair Professor, ASSIST (Seoul School of Integrated Science & Technology)
Finances

Revenue (in USD)  

<table>
<thead>
<tr>
<th>Source</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill &amp; Melinda Gates Foundation (BMGF)</td>
<td>12,378,492</td>
<td>15,205,867</td>
</tr>
<tr>
<td>Government of the Republic of Korea</td>
<td>5,022,300</td>
<td>4,813,476</td>
</tr>
<tr>
<td>Korean Government Laboratory Support</td>
<td>446,978</td>
<td>-</td>
</tr>
<tr>
<td>Swedish International Development Cooperation Agency (Sida)</td>
<td>753,596</td>
<td>780,368</td>
</tr>
<tr>
<td>Corporations / Individuals / Others</td>
<td>9,039,548</td>
<td>5,149,713</td>
</tr>
<tr>
<td>Investments (Interest Income)</td>
<td>115,729</td>
<td>112,108</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>27,796,643</strong></td>
<td><strong>26,061,531</strong></td>
</tr>
</tbody>
</table>

Assets  

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>3,389,308</td>
<td>5,676,076</td>
</tr>
<tr>
<td>Bank Deposits</td>
<td>15,696,083</td>
<td>15,980,280</td>
</tr>
<tr>
<td>Other Current Assets</td>
<td>555,329</td>
<td>763,775</td>
</tr>
<tr>
<td>Other Assets</td>
<td>1,275,619</td>
<td>1,064,298</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>20,916,339</strong></td>
<td><strong>23,484,429</strong></td>
</tr>
</tbody>
</table>

Liabilities and Net Assets  

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant Funds-Deferred Support</td>
<td>11,557,615</td>
<td>15,803,851</td>
</tr>
<tr>
<td>Other Current Liabilities</td>
<td>2,354,718</td>
<td>2,734,583</td>
</tr>
<tr>
<td>Other Liabilities</td>
<td>131,355</td>
<td>-</td>
</tr>
<tr>
<td>Net Assets</td>
<td>6,872,651</td>
<td>4,945,995</td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>20,916,339</strong></td>
<td><strong>23,484,429</strong></td>
</tr>
</tbody>
</table>

Total Expense (in USD)  

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Service</td>
<td>21,409,516</td>
<td>20,009,212</td>
</tr>
<tr>
<td>Laboratory Support</td>
<td>1,514,689</td>
<td>2,188,346</td>
</tr>
<tr>
<td>Management &amp; General</td>
<td>2,496,354</td>
<td>2,223,861</td>
</tr>
<tr>
<td>Communications &amp; Advocacy</td>
<td>521,743</td>
<td>608,234</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td><strong>25,942,303</strong></td>
<td><strong>25,029,653</strong></td>
</tr>
</tbody>
</table>

Foreign Exchange Gain (Loss)  

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign Exchange Gain (Loss)</td>
<td>72,316</td>
<td>179,765</td>
</tr>
</tbody>
</table>

Net Surplus (Deficit)  

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Surplus (Deficit)</td>
<td>1,926,656</td>
<td>1,211,643</td>
</tr>
</tbody>
</table>
Leadership

Jerome Kim, MD
Director General

Phil Driver
Deputy Director General, Finance & Operations

Julia Lynch, MD
Deputy Director General, Development & Delivery

Manki Song, PhD
Head of Clinical Research Lab

Kyung-taik Han, PhD
Deputy Director General, Government & Global Affairs

Florian Marks, PhD
Head of Epidemiology

Viliam Pavlaik, Ph.D
Head of Vaccine Process Development

Scientific Advisory Group (SAG) meeting in session, Dr. Ralf Clemens, Chair